Thermodynamically stable form of a tosylate salt
View Patent ↗The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.
1. A compound of the formula (I)
in the polymorph I form, which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5.
2. The compound of claim 1 which shows in the X-ray diffractometry peak maxima of the 2 theta angle comprising 4.4, 14.8, 20.5, 20.8, 21.5 and 22.9.
3. The compound of claim 1 which shows in the IR spectrum a peak maximum of 1724 cm −1 .
4. The compound of claim 1 which shows in the Raman spectrum a peak maximum of 1723 cm −1 .
5. A method of preparing the compound of formula (I)
in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, comprising contacting a compound of formula (I) in the polymorph II form with an inert solvent under conditions sufficient to quantitatively convert the compound in the polymorph II form to the polymorph I form.
6. The method according to claim 5 , further comprising the step of seeding the inert solvent with crystals of a compound of the formula (I) in the polymorph I form.
7. A method of preparing a compound of formula (I)
in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, comprising heating a compound of formula (I) in the polymorph II form from 195° C. to 222° C. at a heating rate of 10° C. to 30° C. per minute and subsequently cooling to 10° C. to 30° C. at a cooling rate of from 1 to 4° C. per minute.
8. A pharmaceutical composition comprising a compound of formula (I):
substantially in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5.
9. The pharmaceutical composition as claimed in claim 8 , further comprising one or more inert, nontoxic, pharmaceutically suitable excipients.
10. The pharmaceutical composition of claim 8 , wherein the compound of formula (I) is present in the polymorph I form in the composition in an amount equal to or more than 90 percent by weight of the total weight of the compound of formula (I) present in the composition.
11. The pharmaceutical composition according to claim 8 , further comprising another pharmaceutical agent where the combination causes no unacceptable side effects.
12. The pharmaceutical composition of claim 8 , further comprising another pharmaceutical agent which is a cytotoxic agent, a signal transduction inhibitor, an anti-cancer agent, or an antiemetic.
13. A pharmaceutical composition comprising a compound of formula (I):
substantially in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, and at least one additional pharmaceutical agent.
14. The pharmaceutical composition of claim 13 , further comprising one or more inert, nontoxic, pharmaceutically suitable excipients.
15. The pharmaceutical composition of claim 13 , wherein said additional pharmaceutical agent is a cytotoxic agent, a signal transduction inhibitor, an anti-cancer agent, or an antiemetic.
16. A method of treating a disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I)
in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5.
17. The method of claim 16 , wherein the disorder is selected from the group consisting of abnormal angiogenesis, hyperpermeability processes, bone marrow diseases, carcinoma and carcinogenic cell growth.
18. The method of claim 16 , wherein the disorder is leukemia, or carcinoma of the lung, pancreas, thyroid gland, kidney or intestine.
19. A method for treating a disorder, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of any one of claims 8 to 15 .
20. The method of claim 19 , wherein the disorder is selected from the group consisting of abnormal angiogenesis, hyperpermeability processes, bone marrow diseases, carcinoma and carcinogenic cell growth.
21. The method of claim 19 , wherein the disorder is leukemia, or carcinoma of the lung, pancreas, thyroid gland, kidney or intestine.
22. A method of preparing a compound of formula (I)
in the polymorph I form which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, comprising dissolving or suspending a compound of formula (I) in the polymorph II form in an inert solvent and stirring or shaking under conditions sufficient to quantitatively convert the compound in the polymorph II form to the polymorph I form.
23. The compound of the formula (I) as claimed in claim 22 , wherein the process for its preparation further comprises the step of seeding the inert solvent with crystals of a compound of the formula (I) in the polymorph I form.
24. The compound of claim 1 prepared by dissolving or suspending a compound of formula (I) in the polymorph II form in an inert solvent and stiffing or shaking under conditions sufficient to quantitatively convert the compound in the polymorph II form to the polymorph I form.
25. The compound of claim 1 prepared by dissolving or suspending a compound of formula (I) in the polymorph II form in an inert solvent, seeding the inert solvent with crystals of a compound of the formula (I) in the polymorph I form and stiffing or shaking under conditions sufficient to quantitatively convert the compound in the polymorph II form to the polymorph I form.
26. The compound of claim 1 prepared by a method comprising heating a compound of formula (I) in the polymorph II form from 195° C. to 222° C. at a heating rate of 10° C. to 30° C. per minute and subsequently cooling to 10° C. to 30° C. at a cooling rate of from 1 to 4° C. per minute to quantitatively convert the compound in the polymorph II form to the polymorph I form.
27. The compound of claim 1 which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5, which shows in the IR spectrum a peak maximum of 1724 cm −1 and which shows in the Raman spectrum a peak maximum of 1723 cm −1 .
28. A compound having the x-ray diffraction pattern of polymorph I in FIG. 2 of the application which shows in the X-ray diffractometry peak maxima of the 2 theta angle of 4.4, 14.8 and 20.5.
29. The compound of claim 1 which shows in the X-ray diffractometry peak maxima of the 2 theta angle comprising: 4.4, 13.2, 14.8, 16.7, 17.9, 20.1, 20.5, 20.8, 21.5 and 22.9.
30. The compound of claim 1 which shows in the X-ray diffractometry peak maxima of the 2 theta angle comprising: 4.4, 10.7, 11.1, 11.4, 11.6, 12.2, 12.8, 13.2, 14.8, 16.5, 16.7, 17.7, 17.9, 18.8, 19.3, 19.6, 20.1, 20.5, 20.8, 21.5, 21.7, 22.3, 22.5, 22.9, 23.4, 23.7, 24.0, 24.5, 25.1, 25.4, 26.0, 26.4, 26.6, 27.0, 27.6, 28.2, 28.6, 28.8, 29.3, 29.6, 29.9, 30.8, 31.2, 31.6, 31.8, 32.1, 32.4, 32.7, 33.1, 33.8, 34.2, 34.6, 35.4, 35.7 and 37.1.
31. The compound of claim 1 which melts under decomposition at 223° C.-231° C.